Conference call and webcast to be held at
4:30 p.m. EDT
NEW
HAVEN, Conn., Aug. 4, 2022
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing an
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of prurigo nodularis and chronic cough in adults with
idiopathic pulmonary fibrosis (IPF), today announced that
management will host a conference call and live audio webcast on
Thursday, August 11, 2022, at
4:30 p.m. ET, to provide a corporate
update and review the Company's financial results for the second
quarter ended June 30, 2022.
Trevi Therapeutics will host a conference
call on August 11 to review Q2 2022
financial results
To participate in the live conference call by phone, please dial
(888) 317 6003 (domestic) or (412) 317 6061 (international) and
provide access code 9437525. A live audio webcast will be
accessible from the 'Investors & News' section on the Company's
website at www.TreviTherapeutics.com. An archived replay of
the webcast will also be available for 30 days on the Company's
website following the event.
About Trevi Therapeutics,
Inc.
Trevi Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of the investigational therapy Haduvio for the
treatment of prurigo nodularis and chronic cough in adults with
idiopathic pulmonary fibrosis. These conditions share a common
pathophysiology that is mediated through opioid receptors in the
central and peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-release
(ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe.
The ĸ- and µ-opioid receptors are known to be critical mediators of
itch, cough and certain movement disorders. Nalbuphine's mechanism
of action may also mitigate the risk of abuse associated with
µ-opioid agonists because it antagonizes, or blocks, µ-opioid
receptors. Parenteral nalbuphine is not currently scheduled as a
controlled substance by the DEA in the United States or
by regulatory authorities in most
of Europe. Trevi intends to propose Haduvio as the
trade name for nalbuphine ER. Nalbuphine ER has been granted Fast
Track designation by the FDA for the treatment of itch in patients
with prurigo nodularis. Its safety and efficacy have not been
evaluated by any regulatory authority.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q2-2022-financial-results-and-provide-a-corporate-update-on-august-11-2022-301600493.html
SOURCE Trevi Therapeutics, Inc.